Beijing Avistone Pharmaceuticals Biotechnology Co., Ltd._鞍石生物科技是中国创新药企业，旗下拥有两个全资子公司：北京浦润奥生物科技有限责任公司成立于2012年；北京鞍石生物科技有限责任公司成立于2018年。
鞍石生物科技致力于健康服务产业，以为患者提供高质量医药产品作为宗旨。专注于抗肿瘤创新药物的研发，拥有多个药物研发管线，主要研发方向为肿瘤治疗领域”First In Class”及“Best In Class”的创新药物，涵盖肺癌、脑胶质瘤等多个肿瘤治疗领域。
鞍石生物科技始终致力于：通过提供高品质创新药物，让患者生活更有质量，用持续创新为人类健康服务。通过完整
鞍石生物科技致力于健康服务产业，以为患者提供高质量医药产品作为宗旨。专注于抗肿瘤创新药物的研发，拥有多个药物研发管线，主要研发方向为肿瘤治疗领域”First In Class”及“Best In Class”的创新药物，涵盖肺癌、脑胶质瘤等多个肿瘤治疗领域。
鞍石生物科技始终致力于：通过提供高品质创新药物，让患者生活更有质量，用持续创新为人类健康服务。通过完整
Location: China, Beijing
Investors 2
| Date | Name | Website |
| 11.02.2024 | Vivo Capit... | vivocapita... |
| 28.05.2024 | Bain Capit... | baincapita... |
Mentions in press and media 3
| Date | Title | Description |
| 04.01.2024 | Avistone Biotechnology Closes Series B Funding | Avistone Biotechnology, a Beijing, China-based biotechnology company focused on precision oncology therapeutics, closed a Series B financing of ~$140 million USD. The round was led by SDIC CS Capital and IDG Capital, with participation from... |
| 28.12.2023 | Deals in brief: OpenAI seeks fresh funding at valuation north of USD 100 billion, multiple China and India deals, and more | OpenAI is seeking funding at valuation north of USD 100 billion With the dust settling on the leadership tumult at OpenAI, during which Sam Altman was briefly displaced before being reinstated to the CEO position, the artificial intelligenc... |
| - | Avistone Pharmaceuticals | “Beijing Avistone Pharmaceuticals Biotechnology Co., Ltd.” |